Protein diagnostics in the management of monoclonal gammopathies;Il contributo della diagnostica proteica nella gestione delle gammopatie monoclonali

Biochimica Clinica

Volumn 38, Issue 1, 2014, Pages 47-53

  Caldini, Anna ^a   Graziani, Maria Stella ^b   Basile, Umberto ^c   Cataldo, Ivana ^d   Cigliana, Giovanni ^e   Muratore, Maria Teresa ^f   Mussap, Michele ^g   Terreni, Alessandro ^a   Vernocchi, Arialdo ^h   Merlini, Giampaolo ⁱ  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d Ospedale Clinicizzato SS Annunziata   (Italy)

^e REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^f BELCOLLE HOSPITAL   (Italy)

^g UNIVERSITY OF GENOA   (Italy)

^h IRCCS MULTIMEDICA   (Italy)

ⁱ FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84893828913     PISSN: 03930564     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Keren DF. Procedures for the evaluation of monoclonal immunoglobulins. Arch Pathol Lab Med 1999;123:126-32.
2. Graziani MS, Dolci A, Greco C, et al. per il Gruppo di Studio Proteine di SIBioC. Indicazioni per la richiesta di elettroforesi proteica. Biochim Clin 2008;32:48-51.
3. Dolci A, Vernocchi A per il Gruppo di Studio Proteine di SIBioC. Aspetti metodologici nella ricerca e caratterizzazione delle componenti monoclonali nel siero. Biochim Clin 2012;36:84-9.
4. Aguzzi F, Bergami MR, Gasparro C, et al. Occurence of monoclonal components in general practice: clinical implications. Eur J Haematol 1992;48:192-5.
5. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006;354:1362-9.
6. Dispenzieri A, KatzmannJA, Kyle RA, et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet 2010;375:1721-8.
7. Iwanaga M, Tagawa M, Tsukasaki K, et al. Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan. Mayo Clin Proc 2007;82:1474-9.
8. Kyle RA, Rajkumar SV. Epidemiology of the plasma-cell disorders. Best Pract Res Clin Haematol 2007;20:637-64.
9. Kyle RA. Monoclonal gammopathy of undetermined significance. Am J Med 1978;64:814-8.
10. Kyle RA, Therneau TM, Rajkumar SV, et al. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. Mayo Clinic Proc 2004;79:859-66.
11. Merlini G, Stone MJ. Dangerous small B clones. Blood 2006:108:2520-30.
12. Merlini G. Perchè è importante identificare e segnalare le piccole componenti monoclonali. Biochim Clin 2012;36:25-8.
13. Graziani MS, Merlini GP, Petrini C. Linee guida per la ricerca della proteina di Bence Jones. Gruppo di Studio Proteine - Società Italiana di Biochimica Clinica. Biochim Clin 2001;25:23-32.
14. Graziani MS, Merlini GP, Petrini C for the IFCC Committee on Plasma Proteins and the SIBioC Study Group on Proteins. Guidelines for the analysis of Bence Jones Protein. Clin Chem Lab Med 2003;41:338-46.
15. The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749-57.
16. Bird J, Cavenagh J, Hawkins P, et al. on behalf of UK Myeloma Forum. Guidelines on the diagnosis and management of AL amyloidosis. Br J Haematol 2004;125:681-700.
17. Durie BGM, Harousseau JL, Miguel JS, et al. on behalf of the International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-73.
18. Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23:215-24.
19. Kyle RA, Durie BGM, Rajkumar SV, at al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010;24:1121-7.
20. Berenson JR, Kenneth KC, Audell RA, et al. Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol 2010;150:28-38.
21. Bird J, Behrens J, Westin J, et al. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected Mproteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 2010;148:22-42.
22. Dimopoulos M, Kyle R, Fermand JP, et al. Guidelines for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 2011;117:4701-5.
23. Munshi NC, Kenneth C, Anderson KC, et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011;117:4696-700.
24. Tate J, Caldwell G, Daly J, et al. Recommendations for standardized reporting of protein electrophoresis in Australia and New Zealand. Ann Clin Biochem 2012;49:242-56.
25. Luraschi P, Infusino I, Merlotti C, et al. Analytical variation in the measurement of serum monoclonal component by capillary electrophoresis. Clin Chim Acta 2004;349:151-6.
26. Mussap M, Pietrogrande F, Ponchia S, et al. Measurement of serum monoclonal components: comparison between densitometry and capillary zone electrophoresis. Clin Chem Lab Med 2006;44:609-11.
27. Infusino I, Dolci A, Panteghini M. Confronto tra due sistemi per elettroforesi capillare e in gel d'agarosio per la ricerca e caratterizzazione di componenti monoclonali nel siero. Biochim Clin 2008;32:554-8.
28. Whicher JT, Warren C, Chambers RE. Immunochemical assays for immunoglobulins. Ann Clin Biochem 1984;21:78-91.
29. Caldini A, Graziani MS, Terreni A, et al. Indagine sulle modalità di refertazione dell'elettroforesi sieroproteica. Biochim Clin 2009;33:62-5.
30. Harding S, Young P, Di Fazio M, et al. Intact immunoglobulin heavy/light chain paired assays. Biochim Clin 2013;37:365-9.
31. Ludwig H, Milosavljevic D, Zojer N, et al. Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients. Leukemia 2013;27:213-9.
32. Bradwell AR, Carr-Smith HD, Mead GP, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001;47:673-80.
33. AAVV. Catene leggere libere nel siero. Biochim Clin 2013;37:344-437.
34. McTaggart M, Kearney E. Evidence-based use of serum protein electrophoresis in laboratory medicine. Clin Chem Lab Med 2013;51:e113-5.
35. Graziani MS, Merlini GP. Recommendations for appropriate serum electrophoresis requests: the Italian approach. Clin Chem Lab Med 2013;51:e117-8.
36. Merlini G, Palladini G. Differential diagnosis of monoclonal gammopathy of undetermined significance. Hematology Am Soc Hematol Educ Program 2012;2012:595-603.
37. Caldini A, Graziani MS. La determinazione delle catene leggere libere nel siero può sostituire la ricerca e quantificazione della proteinuria di Bence Jones nella pratica clinica?. Biochim Clin 2013;37:405-18.